What the research shows

The FDA granted Forzinity accelerated approval to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. The supporting finding was a gain in knee extensor strength in an open-label extension. A confirmatory trial is required to establish clinical benefit. FDA approval and confirmatory study requirement.

The label describes the trial sequence and the formulation evaluated. Knee extensor strength was an intermediate measure, distinct from an improvement in walking or daily activities. Forzinity prescribing information.

Documented formats

Forzinity is supplied as an injectable solution in single-patient-use vials.

Testing and purity

For an approved-product record, match the manufacturer, vial label and formulation. For a research sample, verify the modified peptide and the salt form against its stated identity.

How to read a batch report

Questions about SS-31 (elamipretide)

Why was knee strength measured?

It quantifies the force used to straighten the knee. The FDA judged that a gain in this measure was reasonably likely to predict patient benefit.

Does the indication cover other mitochondrial conditions?

The cited U.S. indication specifies Barth syndrome, a minimum body weight and an outcome of muscle strength. Other conditions need their own evidence.